Olverembatinib
IIT2022040
Phase 2 small_molecule completed
Quick answer
Olverembatinib for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed